Building Blocks Catalog

300 Thousand compounds in stock

Original and unique

Building Blocks

1B novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

48B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from May 2024

Recent News

  • 21 June 2024   Press Release

    SyntheticGestalt to pioneer Enamine’s В-REAL Space of 38 billion ...

    Tokyo, Japan, and Kyiv, Ukraine, 21 June 2024. SyntheticGestalt, an AI company specializing in the life sciences domain, and Enamine, a pioneer in the creation of ultra-large chemical spaces of highly feasible compounds, announced today a new research program involving the application of AI for novel drug discovery, followed by biological tests of REAL compounds directly at Enamine (B-REAL).

  • 14 June 2024   News

    Continuation of Strategic Partnership between Enamine and Genez

    We are excited to share some news about the strategic partnership between Enamine and Genez International.

  • 16 May 2024   News

    New access point to Enamine REAL - Hyperspace

    We understand the challenges that scientists face while navigating through huge chemical spaces. Our task is to simplify and streamline this process.

    Please welcome a new access point to Enamine REAL Space and Chemspace Freedom Space 3.0 – Hyperspace! It is a fantastic search tool created by our partners from Alipheron.

Upcoming events

Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), has joined the Advanced Machine Learning for Innovative Drug Discovery (AIDD) program, funded by the European Union within the framework of the Marie-Skłodowska-Curie Actions (MSCA) with a budget of Euros 3.93 million. The project, coordinated by Helmholtz Zentrum München,Germany, brings together fifteen institutions from eleven countries in addition to the University of British Columbia (Canada) to train sixteen PhD students in close collaboration with associated partners from the USA, Australia, China, Israel and other countries and develop next generation AI and Machine Learning (ML) models and systems for drug discovery.